Skip to main content

Table 5 Levels of serum AGEP, VCAM-1, HIF-1α, VEGF, and CTRP3 in all the studied groups

From: Association study of HIF-1α rs11549465 and VEGF rs3025039 genetic variants with diabetic retinopathy in Egyptian patients: crosslinks with angiogenic, inflammatory, and anti-inflammatory markers

 

Control (n = 72)

DWR (n = 72)

NPDR (n = 72)

PDR (n = 72)

AGEP (μg/ml)

19.02 (21.26)

223.96 (155.22)

799.16 (794.37)

786.00 (713.09)

P value

 

< 0.0001a

< 0.0001a, b

< 0.0001a, b/ 1.000c

VCAM-1 (ng/ml)

117.00 (47.65)

378.25 (47.22)

589.90 (399.70)

682.80 (461.80)

P value

 

< 0.0001a

< 0.0001a, b

< 0.0001a, b/ 0.983c

HIF-1α (pg/ml)

8.42 (4.12)

10.28 (4.48)

16.92 (5.19)

18.03 (3.93)

P value

 

< 0.076a

< 0.0001a, b

< 0.0001a, b/ 1.000c

VEGF (pg/ml)

84.43 (4.76)

85.95 (3.25)

89.35 (12.69)

98.30 (6.80)

P value

 

0.306a

< 0.0001a, b

< 0.0001a, b/ 0.041c

CTRP3 (ng/ml)

20.27 (7.97)

10.32 (5.70)

3.16 (2.64)

3.34 (3.53)

P value

 

< 0.0001a

< 0.0001a, b

< 0.0001a, b/ 1.000c

  1. Data are expressed median (interquartile range)
  2. DWR diabetes without retinopathy, NPDR non-proliferative retinopathy, PDR proliferative diabetic retinopathy, AGEP advanced glycation end products, VCAM-1 vascular cell adhesion molecule-1, HIF-1α hypoxia-inducible factor-1 alpha, VEGF vascular endothelial growth factor, CTRP3 C1q tumor necrosis factor-related protein 3
  3. aSignificance versus control group
  4. bSignificance versus DWR group
  5. cSignificance versus NPDR group
  6. Significance had been adjusted by Bonferroni correction for multiple tests
  7. The mean difference is significant at p < 0.05